Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Kawana-Tachikawa A, Llibre JM, Bravo I, Escrig R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C; MARAVIBOOST Investigators. Kawana-Tachikawa A, et al. Among authors: escrig r. PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014. PLoS One. 2014. PMID: 24475275 Free PMC article. Clinical Trial.
Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
Negredo E, Domingo P, Pérez-Álvarez N, Gutiérrez M, Mateo G, Puig J, Escrig R, Echeverría P, Bonjoch A, Clotet B. Negredo E, et al. Among authors: escrig r. J Antimicrob Chemother. 2014 Dec;69(12):3368-71. doi: 10.1093/jac/dku300. Epub 2014 Aug 13. J Antimicrob Chemother. 2014. PMID: 25125679 Clinical Trial.
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.
Negredo E, Diez-Pérez A, Bonjoch A, Domingo P, Pérez-Álvarez N, Gutierrez M, Mateo G, Puig J, Echeverría P, Escrig R, Clotet B. Negredo E, et al. Among authors: escrig r. J Antimicrob Chemother. 2015 Jul;70(7):2104-7. doi: 10.1093/jac/dkv063. Epub 2015 Mar 13. J Antimicrob Chemother. 2015. PMID: 25769303
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.
Rosás-Umbert M, Ruiz-Riol M, Fernández MA, Marszalek M, Coll P, Manzardo C, Cedeño S, Miró JM, Clotet B, Hanke T, Moltó J, Mothe B, Brander C; BCN02 study group. Rosás-Umbert M, et al. Front Immunol. 2020 Mar 20;11:418. doi: 10.3389/fimmu.2020.00418. eCollection 2020. Front Immunol. 2020. PMID: 32265913 Free PMC article. Clinical Trial.
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control.
Borgognone A, Noguera-Julian M, Oriol B, Noël-Romas L, Ruiz-Riol M, Guillén Y, Parera M, Casadellà M, Duran C, Puertas MC, Català-Moll F, De Leon M, Knodel S, Birse K, Manzardo C, Miró JM, Clotet B, Martinez-Picado J, Moltó J, Mothe B, Burgener A, Brander C, Paredes R; BCN02 Study Group. Borgognone A, et al. Microbiome. 2022 Apr 11;10(1):59. doi: 10.1186/s40168-022-01247-6. Microbiome. 2022. PMID: 35410461 Free PMC article. Clinical Trial.
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J; IntegRal Collaborative Group. Massanella M, et al. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):152-60. doi: 10.1097/QAI.0b013e318289439a. J Acquir Immune Defic Syndr. 2013. PMID: 23392458
The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses.
Plana M, Garcia F, Darwich L, Romeu J, López A, Cabrera C, Massanella M, Canto E, Ruiz-Hernandez R, Blanco J, Sánchez M, Gatell JM, Clotet B, Ruiz L, Bofill M; Red de Investigación en Sida (RIS). Plana M, et al. Immunology. 2011 Jul;133(3):318-28. doi: 10.1111/j.1365-2567.2011.03442.x. Epub 2011 Apr 19. Immunology. 2011. PMID: 21501161 Free PMC article. Clinical Trial.
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, Rosas-Umbert M, Cobarsi P, Escrig R, Perez-Alvarez N, Ruiz I, Rovira C, Meulbroek M, Crook A, Borthwick N, Wee EG, Yang H, Miró JM, Dorrell L, Clotet B, Martinez-Picado J, Brander C, Hanke T. Mothe B, et al. Among authors: escrig r. EClinicalMedicine. 2019 Jun 5;11:65-80. doi: 10.1016/j.eclinm.2019.05.009. eCollection 2019 May-Jun. EClinicalMedicine. 2019. PMID: 31312806 Free PMC article.
Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80.
Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, Rosas-Umbert M, Cobarsi P, Escrig R, Perez-Alvarez N, Ruiz I, Rovira C, Meulbroek M, Crook A, Borthwick N, Wee EG, Yang H, Miró JM, Dorrell L, Clotet B, Martinez-Picado J, Brander C, Hanke T; BCN 01 study group. Mothe B, et al. Among authors: escrig r. EClinicalMedicine. 2020 Jan 10;18:100250. doi: 10.1016/j.eclinm.2019.100250. eCollection 2020 Jan. EClinicalMedicine. 2020. PMID: 31956858 Free PMC article.
42 results